SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-004285 to PULSE BIOSCIENCES, INC. (PLSE)

PULSE BIOSCIENCES, INC.
Date: April 18, 2024 · CIK: 0001625101 · Accession: 0000000000-24-004285

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-278494

Date
April 18, 2024
Author
Kevin Danahy
Form
UPLOAD
Company
PULSE BIOSCIENCES, INC.

Letter

United States securities and exchange commission logo April 18, 2024 Kevin Danahy Chief Executive Officer Pulse Biosciences, Inc. 3957 Point Eden Way Hayward, CA 94545 Re:Pulse Biosciences, Inc. Amendment No. 1 to Registration Statement on Form S-3 Filed April 15, 2024 File No. 333-278494 Dear Kevin Danahy: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our April 10, 2024 letter. Amendment No. 1 to Registration Statement on Form S-3 Material U.S. Federal Income Tax Consequences, page 31 1.We note your response to comment 2, but we are not persuaded by your response and reissue the comment. Please file a tax opinion as an exhibit to the filing. We refer you to Section III.A.1 of Staff Legal Bulletin 19.

FirstName LastNameKevin Danahy Comapany NamePulse Biosciences, Inc. April 18, 2024 Page 2 FirstName LastName Kevin Danahy Pulse Biosciences, Inc. April 18, 2024 Page 2 Please contact Juan Grana at 202-551-6034 or Jane Park at 202-551-7439 with any other questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Adam Finerman, Esq.

Show Raw Text
United States securities and exchange commission logo
April 18, 2024
Kevin Danahy
Chief Executive Officer
Pulse Biosciences, Inc.
3957 Point Eden Way
Hayward, CA 94545
Re:Pulse Biosciences, Inc.
Amendment No. 1 to Registration Statement on Form S-3
Filed April 15, 2024
File No. 333-278494
Dear Kevin Danahy:
            We have reviewed your amended registration statement and have the following comment.
            Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
            After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments. Unless we note otherwise,
any references to prior comments are to comments in our April 10, 2024 letter.
Amendment No. 1 to Registration Statement on Form S-3
Material U.S. Federal Income Tax Consequences, page 31
1.We note your response to comment 2, but we are not persuaded by your response and
reissue the comment. Please file a tax opinion as an exhibit to the filing. We refer you to
Section III.A.1 of Staff Legal Bulletin 19.

 FirstName LastNameKevin Danahy
 Comapany NamePulse Biosciences, Inc.
 April 18, 2024 Page 2
 FirstName LastName
Kevin Danahy
Pulse Biosciences, Inc.
April 18, 2024
Page 2
            Please contact Juan Grana at 202-551-6034 or Jane Park at 202-551-7439 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Adam Finerman, Esq.